You are here:

salmeterol xinafoate fluticasone propionate combination inhaler (Seretide)

Advice

Following a resubmission

salmeterol/fluticasone 50/500 micrograms inhaler (Seretide 500 Accuhaler) is not recommended for use within NHS Scotland for the symptomatic treatment of patients with chronic obstructive airways disease (COPD) with a forced expiratory volume in 1 second (FEV1) 50% to <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

While there were improvements in lung function tests and reductions in moderate exacerbations with the salmeterol/fluticasone combination compared to placebo and to salmeterol alone, there were no significant differences in mortality rates over 3 years. In addition, the manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.

Drug Details

Drug Name: salmeterol xinafoate fluticasone propionate combination inhaler (Seretide)
SMC Drug ID: 450/08
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Symptomatic treatment of patients with chronic obstructive pulmonary disease (COPD)
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 12 January 2009

Archived Advice

Full submission 10 March 2008

Back